Recent Updates — TVTX

Travere Therapeutics announced that Eric Dube will step down as President and CEO effective December 1, 2026. Bradley L. Campbell has been appointed as his successor in both roles on the same date. Dr. Dube will serve as Executive Advisor through February 15, 2027, to facilitate transition. Mr. Campbell brings over 25 years of biopharmaceutical experience, previously serving as CEO of Amicus Therapeutics until its acquisition by BioMarin in April 2026. His employment agreement includes a $1 million base salary, target bonus of 85%, and initial equity awards valued at approximately $16.5 million, plus a potential $3.75 million performance-based award. The company operates in the biopharmaceutical industry.

Sandra Calvin, the chief accounting officer and principal accounting officer, announced her intention to retire in February 2027 following the filing of the company's Annual Report on Form 10-K. John Torell, the current Vice President and Controller, is expected to succeed her in those roles to ensure an orderly transition. Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

William Rote, Ph.D., Chief Research Officer, announced his intention to retire on February 17, 2027. Jula Inrig, M.D., current Chief Medical Officer, will be named Executive Vice President, Head of Research & Development and Chief Medical Officer effective July 1, 2026. Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutic solutions for rare diseases.